Brent Gutekunst et al.Download PDFPatent Trials and Appeals BoardMay 1, 20202019000057 (P.T.A.B. May. 1, 2020) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 15/356,342 11/18/2016 Brent GUTEKUNST TCHD/0002USC01 2235 26290 7590 05/01/2020 PATTERSON + SHERIDAN, L.L.P. 24 Greenway Plaza, Suite 1600 Houston, TX 77046 EXAMINER ROSE, DERRICK V ART UNIT PAPER NUMBER 2462 NOTIFICATION DATE DELIVERY MODE 05/01/2020 ELECTRONIC Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es): PSDocketing@pattersonsheridan.com jcardenas@pattersonsheridan.com pair_eofficeaction@pattersonsheridan.com PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte BRENT GUTEKUNST, DARIN OKUDA, LAURIE BABB, and VIC MARKARIAN Appeal 2019-000057 Application 15/356,342 Technology Center 2400 Before JOSEPH L. DIXON, ST. JOHN COURTENAY III, and LARRY J. HUME, Administrative Patent Judges. HUME, Administrative Patent Judge. DECISION ON APPEAL Pursuant to 35 U.S.C. § 134(a), Appellant1 appeals from the Examiner’s decision rejecting claims 55–58, 60–63, 66–76, 79–81, 83, and 842. Appellant has canceled claims 1–54, 64, 65, 77, and 78. With no outstanding rejections, objections, indication of allowance, or cancellation of record, claims 59 and 82 are not before us on Appeal. We have jurisdiction under 35 U.S.C. § 6(b). We REVERSE. 1 We use the word “Appellant” to refer to “applicant” as defined in 37 C.F.R. § 1.42(a). Appellant identifies the real party in interest as TouchDX, Inc. Appeal Br. 3. 2 See TABLE 1, infra, for clarification of the pending and rejected claims. Appeal 2019-000057 Application 15/356,342 2 STATEMENT OF THE CASE3 The Invention The claims are directed “to medical surveillance testing, assessing, and monitoring.” Spec. ¶ 2. In particular, Appellant’s disclosed embodiments and claimed invention relate “to apparatus, systems, and articles of manufacture for configuring general purpose portable communication devices for medical surveillance testing, assessing, monitoring, and processing information received from such devices.” Id. Exemplary Claim Claim 55, reproduced below, is representative of the subject matter on appeal (emphases added to contested prior-art limitations): 55. A method for sharing medical data between applications on a user device, the method comprising: maintaining a data store on the user device; executing an initialization application on the user device, the initialization application being configured to manage a plurality of configuration files corresponding to a plurality of applications on the user device, each of the configuration files comprising one or more key value pairs, each key value pair comprising identifying data matched with data that defines an operating parameter for at least one of the plurality of applications; executing a first application of the plurality of applications based on a first configuration file of the plurality of 3 Our decision relies upon Appellant’s Appeal Brief (“Appeal Br.,” filed Apr. 26, 2018); Reply Brief (“Reply Br.,” filed Oct. 1, 2018); Examiner’s Answer (“Ans.,” mailed Aug. 13, 2018); Non-Final Office Action (“Non- Final Act.,” mailed Dec. 7, 2017); and the original Specification (“Spec.,” filed Nov. 18, 2016). Appeal 2019-000057 Application 15/356,342 3 configuration files, the first configuration file including a first key value pair that defines an access level to the data store; executing a second application of the plurality of applications based on a second configuration file of the plurality of configuration files, the second application being different than the first application, the second configuration file including a second key value pair that defines an access level to the data store; storing, by the first application, medical data in the data store based on the access level defined by the first key value pair; accessing, by the second application, the medical data in the data store based on the access level defined by the second key value pair; performing a medical test for a user with the user device; determining a metric based on the medical test; and triggering an event based on a comparison of the medical test to a threshold, wherein the event comprises sending information indicative of the comparison to a computing device. Appeal 2019-000057 Application 15/356,342 4 Prior Art The Examiner relies upon the following prior art as evidence in rejecting the claims on appeal: Panasik et al. (“Panasik”) US 2005/0208925 A1 Sept. 22, 2005 Garza-Gonzalez et al. (“Garza-Gonzalez”) US 2006/0130150 A1 June 15, 2006 Aggarwal et al. (“Aggarwal”) US 2007/0100987 A1 May 3, 2007 Sklovsky et al. (“Sklovsky”) US 2009/0247077 A1 Oct. 1, 2009 Nolan et al. (“Nolan”) US 2009/0326980 A1 Dec. 31, 2009 Chene et al. (“Chene”) US 2010/0049874 A1 Feb. 25, 2010 Cohen et al. (“Cohen”) US 2010/0286488 A1 Nov. 11, 2010 Rofougaran US 2010/0321304 A1 Dec. 23, 2010 Yoo et al. (“Yoo”) US 2011/0025611 A1 Feb. 3, 2011 Jung et al. (“Jung”) US 2012/0164613 A1 June 28, 2012 Rejections on Appeal4 The Examiner makes several typographical errors and/or omissions in the Non-Final Action. To clarify the various rejections and claims before us on Appeal, TABLE 1 is provided below: 4 Although claims 59 and 82 were included in the list of rejected claims 55–84 on the Non-Final Office Action Summary page, we find no detailed statement of rejection to review for claims 59 and 82 in the Non-Final Action, mailed Dec. 7, 2017, from which this Appeal is taken. Nor does the Examiner indicate in the record that claims 59 and 82 are allowable or objected to. Therefore, the status of claims 59 and 82 is unclear on appeal, and we have no jurisdiction under 35 U.S.C. §6(b) as to any claims that were not rejected. Accordingly, claims 59 and 82 are not before us on appeal. We further bring to the Examiner’s attention that claim 82 is an independent claim. Appeal 2019-000057 Application 15/356,342 5 TABLE 1 — CLARIFICATION OF CLAIM STATUS Rej. No. Claims Expressly Rejected5 Detailed Rejection6 Claims Without Detailed Rejection7 Canceled Claims Claims not Rejected or Canceled8 R1 55-58, 60- 62, 64, 70- 76, 83 55-58, 60, 61, 66, 70-74, 79, 83, 84 62, 64, 75, 76 1-54, 64, 65, 77, 78 59, 82 R2 62, 75 62, 75 R3 63, 76 63, 76 R4 67, 80 67, 80 R5 68, 81 68, 81 R6 69, 83 69, 839 R1. Claims 55–58, 60, 61, 66, 70–74, 79, 83, and 8410 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, and Garza-Gonzalez. Non-Final Act. 2. 5 “Claims Expressly Rejected” are claims indicated as being rejected by the Examiner in the express statement (heading) of the rejection, but where no relevant findings are provided within the body of the detailed rejection. 6 “Detailed Rejection” refers to claims for which a detailed rejection is provided in the Non-Final Action, whether or not these claims are addressed in the express statement of the rejection. 7 “Claims Without Detailed Rejection” refers to claims not rejected within the detailed rejection, but included in the express statement (heading) of the rejection. 8 See n.3, supra, regarding why claims 59 and 82 which are not rejected nor canceled are not before us on Appeal. 9 We note claim 83 is twice rejected, under both Rejections R1 and R6. 10 Claims listed in the express statement of the rejection (heading) by the Examiner are corrected to match those in the body of the rejection. Appeal 2019-000057 Application 15/356,342 6 R2. Claims 62 and 75 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, and Rofougaran. Non-Final Act. 7. R3. Claims 63 and 76 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, and Panasik. Non-Final Act. 9. R4. Claims 67 and 80 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, and Nolan. Non-Final Act. 11. R5. Claims 68 and 81 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, and Yoo. Non-Final Act. 12. R6. Claims 69 and 83 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over the combination of Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, and Jung. Non-Final Act. 14. ISSUES AND ANALYSIS Based upon our review of the record, we find a preponderance of the evidence supports particular arguments advanced by Appellant with respect to claims 55–58, 60–63, 66–76, 79–81, 83, and 84 for the specific reasons discussed below. We highlight and address specific findings and arguments for emphasis as follows. Appeal 2019-000057 Application 15/356,342 7 1. § 103 Rejection R1 of Claims 55–58, 60, 61, 66, 70–74, 79, 83, 8411 Issue 1 Appellant argues (Appeal Br. 23; Reply Br. 2–3) the Examiner’s rejection of claims 55, 72, and 84 under 35 U.S.C. § 103(a) as being obvious over the combination of Chene, Cohen, Sklovsky, Aggarwal, and Garza- Gonzalez is in error. These contentions present us with the following issue: Did the Examiner err in finding the cited prior art combination teaches or suggests a method for sharing medical data between applications on a user device that includes, inter alia, the step of “storing, by the first application, medical data in the data store based on the access level defined by the first key value pair,” as recited in claim 55, and as similarly recited in each of independent claims 72 and 84? ANALYSIS The Examiner finds Chene, Cohen, Sklovsky, and Aggarwal “are silent where the first and second configuration files including a first and second key value pair that defines access levels to the data store.” Non- Final Act. 4. Instead, the Examiner finds “Garza-Gonzales remedies this deficiency.” Id. (citing Garza-Gonzales ¶¶ 2, 24–25, 32). With respect to arguments submitted regarding the Examiner’s failure to address certain of Appellant’s contentions, Appellant submits: [T]he Examiner fails to show that the cited art discloses “storing, by the first application, medical data in the data store based on the access level defined by the first key value pair” or 11 Claim 84 was not included in the rejection heading of Rejection R1, but is included in the body of the rejection. Non-Final Act. 2–3. Appeal 2019-000057 Application 15/356,342 8 “accessing, by the second application, the medical data in the data store based on the access level defined by the second key value pair,” as recited in claim 55 and similarly claims 72 and 84. By failing to address each and every limitation of the claims, the Examiner fails to make a prima facie case of obviousness. Appeal Br. 23 (“Unaddressed Claim Limitations”) (emphasis added). We disagree with the Examiner because, for the reasons set forth by Appellant, we do not find the cited portions of Garza-Gonzales teach or suggest the disputed limitation, i.e., “storing, by the first application, medical data in the data store based on the access level defined by the first key value pair,” as recited in claim 55 (emphasis added). We disagree with the Examiner because we find Garza-Gonzales provides no teaching or suggestion that the first application stores medical data based on an access level defined by the first key value pair. Therefore, for essentially the same reasons argued by Appellant, we reverse the Examiner’s rejection of independent claim 55, and also of independent claims 72 and 84, rejected on the same basis, and which recite the disputed limitation in commensurate form.12 Because we have reversed independent claims 55 and 72 under Rejection R1, we also reverse dependent claims 56–58, 60, 61, 66, 70, 71, 73, 74, 79, and 83, which variously and ultimately depend from independent claims 55 and 72. 12 Because we agree with at least one of the dispositive arguments advanced by Appellant, we need not reach the merits of Appellant’s other arguments. See Beloit Corp. v. Valmet Oy, 742 F.2d 1421, 1423 (Fed. Cir. 1984) (finding an administrative agency is at liberty to reach a decision based on “a single dispositive issue”). Appeal 2019-000057 Application 15/356,342 9 2. § 103 Rejections R2–R6 of Claims 62, 63, 67–69, 75, 76, 80, 81, 83 Because we have reversed Rejection R1 of independent claims 55, 72, and 84, we also reverse Rejections R2–R6 of independent claims 62, 63, 68, 69, 75, 76, and 81, which all recite the disputed limitation in commensurate form, and which all rely upon the disclosure of Garza-Gonzales to teach or suggest the disputed limitation. In light of our reversal of independent claims 55 and 72, supra, we also reverse obviousness Rejections R4 and R6 of dependent claims 67, 80, and 83, which variously and ultimately depend from independent claims 55 and 72, and which stand therewith. On this record, the Examiner has not shown how the additionally cited references in Rejections R2 through R6 overcome the aforementioned deficiencies with Garza-Gonzales, as discussed above regarding claim 55. CONCLUSION The Examiner erred with respect to obviousness Rejections R1–R6 of claims 55–58, 60–63, 66–76, 79–81, 83, and 84 under 35 U.S.C. § 103(a) over the cited prior art combinations of record, and we do not sustain the rejections. Claims 59 and 82 have not been rejected by the Examiner and therefore are not before us on Appeal. See n.3, supra. Appeal 2019-000057 Application 15/356,342 10 DECISION SUMMARY Claims Rejected 35 U.S.C § Basis/ References Affirmed Reversed 55-58, 60, 61, 66, 70-74, 79, 83, 84 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez 55-58, 60, 61, 66, 70-74, 79, 83, 84 62, 75 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, Rofougaran 62, 75 63, 76 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, Panasik 63, 76 67, 80 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, Nolan 67, 80 68, 81 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, Yoo 68, 81 69, 83 103(a) Obviousness Chene, Cohen, Sklovsky, Aggarwal, Garza-Gonzalez, Jung 69, 83 Overall Result 55–58, 60– 63, 66–76, 79–81, 83, 84 REVERSED Copy with citationCopy as parenthetical citation